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E-mail address: rtfjb1@criba.edu.ar (F.J. Barrantes)Alzheimer’s disease (AD) is one of the most devastating diseases of the central nervous system (CNS).
It is characterized by two neuropathological ﬁndings: amyloid plaques and neuroﬁbrillary tangles.
AD is also accompanied by an extensive functional deﬁcit in the cholinergic system, involving the
neuronal-type nicotinic acetylcholine receptor (AChR). Furthermore there is increasing evidence
showing a misregulation of cholesterol metabolism in the development of the disease. Since choles-
terol affects AChR protein at multiple levels, the cognitive impairment and other neurological cor-
relates of AD might be partly associated with an abnormal crosstalk between the receptor protein
and the sterol in this synaptopathy.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is one of the most common aging-re-
lated diseases of the central nervous system (CNS). AD, dementia
with Lewy bodies, and Pick’s disease are three forms of dementia
associated with pathological protein aggregation and inclusion
body formation. In AD the two prevailing neuropathological ﬁnd-
ings in postmortem brains are senile-amyloid-plaques, mainly
composed of deposits of the amyloid peptide (Ab), and neuroﬁbril-
lar tangles, composed of hyperphosphorylated tau protein. Ab is
generated from the amyloid precursor protein (APP) by enzymatic
cleavage through b and c secretases. In normal individuals Ab40
represents the major component of the total Ab pool in brain,
whereas in brains of patients suffering from AD this ratio is altered
and the levels of Ab42 are much higher. Ab42 is highly ﬁbrillogenic
and has toxic effects on neurons [1]. AD is also accompanied by
extensive neuronal loss, especially in the cholinergic system,
involving most conspicuously the neuronal-type nicotinic acetyl-
choline receptor (AChR).
Historically, the ‘‘cholinergic hypothesis” of AD is based on one
of the earliest neuropathological abnormalities in this disease: the
degeneration of cholinergic neurons located in the basal forebrain
[2]. Abundant postmortem and antemortem studies in elderly hu-chemical Societies. Published by E
.mans and AD patients have reported a large number of cholinergic
abnormalities including decreases in choline acetyltransferase
activity and acetylcholine release, loss of AChR and muscarinic
receptor expression early in the disease, defective high-afﬁnity
choline uptake or dysfunctional neurotrophin support, all of which
positively correlate with cognitive decline and non-cognitive
behavioral disturbances as well as with the deposition of toxic
neuritic plaques [2]. More recent studies provide a new twist to
the cholinergic hypothesis, focusing on a particular subtype of neu-
ronal cholinergic receptor: Ab binds with high afﬁnity to the a7
AChR on neuronal cell surfaces, a process that may constitute a
precipitating event in the formation of amyloid plaques [1].
The a7-type of neuronal AChR is an homopentameric ligand-
gated ion channel that belongs to the family of Cys-looped recep-
tors. It transduces the binding of at least two acetylcholine (ACh)
molecules into a rapidly desensitizing Ca2+ inﬂux. This type of
receptor is widely expressed throughout the mammalian brain
and is involved in sensory gating, learning, memory formation
and neuroprotection. Due to its high Ca2+ permeability it partici-
pates in various signal transduction mechanisms such as the
ERK/MAPK and the JAK2/PIP3K cascades, promoting neuronal sur-
vival by inducing the production of the anti-apoptotic proteins Bcl-
s and Bcl-x [1] (see Fig. 1).
There is increasing evidence that lipid homeostasis is misbal-
anced in brains of AD patients. In particular, cholesterol metabo-
lism seems to be affected and has recently become an importantlsevier B.V. All rights reserved.
Fig. 1. Involvement of the neuronal a7 AChR in signal transduction cascades. Cholinergic transmission mediated by the a7 AChR is important in sensory gating, learning, and
memory formation, and its derangement is increasingly acknowledged as a hallmark of AD. (A) When two molecules of the natural neurotransmitter ACh or other cholinergic
agonists bind to the a7 AChR at the neuronal surface, the channel opens and a rapidly desensitizing Ca2+-driven ion current ensues. Calcium ions can participate in a variety of
intracellular processes; the diagram schematically depicts two key signal transduction cascades associated with a7 AChR gating: the ERK/MAPK and the JAK2/PI3K cascades,
activation of which promotes neuronal survival. In AD, chronic a7 AChR-dependent activation of the ERK/MAPK cascade by Ab overburdens the cascade and signal
transduction fails [1,26]. (B) ApoE peptides behave as non-competitive antagonists of a7 AChRs. ApoE may thus contribute to the cognitive decline characteristic of AD by
interfering with cholinergic neurotransmission. (C) The amyloid peptide Ab42 binds to the a7 AChR at the surface of neurons with very high (pM) afﬁnity, competing with the
normal Ca2+ activation, and resulting in endocytic internalization of the AChR–Ab42 complex, especially in neurons with high levels of expression of a7 AChRs, and
intracellular accumulation in the lysosomal compartment. Ab42 aggregation can in turn promote phosphorylation of the microtubular tau protein and the formation of
neuroﬁbrilar tangles.
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synthesis in the brain does not appear to depend on the circulating
pool of steroids and furthermore, plasma lipoproteins cannot cross
the blood–brain barrier (BBB) [3]. In the adult brain mature neu-
rons progressively lose the ability to synthesize cholesterol and
therefore acquire it from glial cells, particularly from astrocytes
[4]. Therefore, astrocytes can be envisaged as the locus of choles-
terol homeostasis in the adult brain since they are able not only
to synthesize, but also to internalize and recycle the cholesterol re-
leased from degenerating nerve terminals to deliver it back to neu-
rons [5]. In healthy people the exchange of cholesterol between the
CNS and the circulating blood is hindered by the BBB, whereas in
AD patients the reverse passage of cholesterol from the CNS to
the venous circulation appears to be reduced, and transport of cho-
lesterol coming from degenerating neurons appears to be in-
creased. This latter activity requires cholesterol binding to
apolipoprotein E (ApoE) [5].In this short overview we discuss available evidence pointing to
the possible involvement of, and mutual interactions between, a7
AChR and cholesterol in AD.2. a7 AChR, cognitive brain functions and AD
Several lines of evidence link brain a7 AChR with the develop-
ment of AD [6]. Firstly, the a7 AChR subunit gene (CHRNA7) is lo-
cated in the highly duplicated 15q13–q14 region implicated in
several neuropsychiatric disorders, including schizophrenia and
bipolar affective disorder. The CHRNA7 gene is duplicated from
exons 5 to 10, with more than 99% identity at the nucleotide level
[7]. Biochemical analyses of postmortem brains show decreased
amounts of AChRs in AD patients. The most vulnerable neurons ap-
pear to be those expressing high levels of a7 AChR [8]. Further-
more, the a7-type AChR is highly expressed in brain regions
1858 F.J. Barrantes et al. / FEBS Letters 584 (2010) 1856–1863relevant to memory functions and involved in the processing of
sensory information, such as the basal forebrain cholinergic neu-
rons that project to the hippocampus and cortex [9].
A distinctive property of the a7 AChR is its ability to modulate
Ca2+ homeostasis and the release of the natural neurotransmitter,
ACh, two functions playing a major role in cognition and memory.
AChRs have also been postulated to exert a neuromodulatory role
on glutamate-mediated excitatory synaptic transmission [10]. If
one further considers the involvement of a7 AChRs in synaptic
plasticity [11] this subtype of receptors constitutes a key target
for understanding the molecular dysfunctions involved in AD and
for the development of new drugs to ameliorate or treat this dis-
ease. It is worth mentioning that nicotine treatment has been
shown to improve attention, as well as learning and memory per-
formance in patients with mild to moderate AD, as do drugs that
potentiate central cholinergic function [12].
The mechanistic link between the affectations of nicotinic cho-
linergic pathways with the cognitive decline in AD is still far from
being understood. One of the obvious inferences is that at least
some of the pathognomonical behavioral alterations, such as the
episodic memory impairment observed in AD, reﬂect compromised
cholinergic neurotransmission and this in turn is a sign of abnormal
AChR function. Indeed, nicotinic ligand binding studies of postmor-
tem brains as well as in vivo positron emission tomography have
shown that there is a marked reduction in the number of different
subtypes of AChRs in various brain areas of individuals with AD
[13,14]. Cholinergic input to the hippocampus and neocortex stems
mainly from the basal forebrain, including the medial septal nu-
cleus, diagonal band nuclei, and nucleus basalis. Cholinergic projec-
tion neurons within cortical areas are deﬁcient in AChR. In
particular, there is evidence that Ab42 binds to the a7 AChR with
very high (pM) afﬁnity and that both are present in neuritic amyloid
plaques of human brains with AD [1]. Short exposure times and
moderate concentrations (pM–nM) of Ab42 do not lead to perma-
nent changes in a7 AChR or the ERK MAPK cascade; higher doses
and extended exposure time lead to dysregulation of a7 AChR,
ERK MAPK, and CREB, as well as deﬁcits in memory and learning.
The intraneuronal accumulation of Ab42 is apparently facilitated
by its high-afﬁnity binding to the a7 AChR. Activation by the latter
mediates Ab-induced tau protein phosphorylation, which in turn
involves the activation of the ERK MAPK and JNK-1 MAPK cascades
(Fig. 1). A signiﬁcant decrease in a7 AChR protein expression – but
not in the amount of mRNA – takes place in the temporal cortex of
AD brains, suggesting that the loss of a7 AChR does not occur at the
transcriptional level. Reports that correlate deﬁcits in synaptic plas-
ticity, learning, and memory with increases in intraneuronal Ab
may reﬂect the consequences of the interaction between Ab and
a7 AChR [15]. A recent study using a transgenic mouse model of
AD overexpressing a mutated form of the human APP [16] on the
background of a knockout mouse for the a7 AChR [17] established
that deletion of the a7 AChR gene leads to a reduction in cognitive
deﬁciency and an improvement in synaptic physiology [18]. It is
interesting to note that this occurs despite the presence of high
amounts of APP and amyloid deposits, further highlighting the
importance of a7 AChR in the pathology of AD and suggesting that
a7 AChR is required to develop the cognitive impairment observed
in AD [18]. Deletion of a7 AChR also protected from loss of the syn-
apticmarkers synaptophysin andMAP2 and preserved the ability to
elicit long-term potentiation otherwise deﬁcient in APP mice. The
authors speculate that interfering with a7 AChR function could be
beneﬁcial in the treatment of AD.
There is still uncertainty as to the nature of the pharmacological
effects of Ab on a7 AChR [19]. Some reports indicate that Ab can act
as an agonist of the a7 AChR whereas other reports point to inhib-
itory effects [1]. Ab blocks long-term potentiation, a correlate of
learning, through activation of MAPK and JNK. Other studies evensuggest that Ab does not interact at all with the a7 AChR but exerts
its deleterious action by interacting with membrane lipids in the
vicinity of the receptor [20]. Human neuroblastoma cells over-
expressing a7 AChR are killed by Ab42, a7 AChR agonists exerting
a protecting effect on cell survival. Small et al. [20] reported that Ab
disturbs intracellular signal transduction mechanisms mediated by
the a7 AChR in SH-SY5Y cells by decreasing plasma membrane ﬂu-
idity. Studies from our laboratory and others have documented
that changes in membrane ﬂuidity or lipid distribution correlate
with changes in AChR function (reviewed in Ref. [22]). Ab has also
been reported to inhibit a7 AChR-dependent calcium activation
and ACh release [1]. Endocytosis of Ab42 is enhanced by its binding
to the a7 AChR; in fact the AChR–Ab42 complex appears to be co-
internalized and accumulated in lysosomes [8]. Ab also affects the
endocytosis of the NMDA receptor; upon a7 AChR stimulation,
NMDA receptors are internalized in an Ab-dependent manner,
leading to a weakening of synaptic strength [21]. The observation
that the interaction of Ab peptides with a7 AChRs occurs at phys-
iological concentrations of the peptide led to the suggestion that
Ab42 acts as an endogenous ligand of the a7 AChR [1]. Therefore,
anomalous interactions of Ab with the a7 AChR at high peptide
concentrations have been invoked in the pathology of the AD.
One possible consequence of this anomalous interaction could be
the phosphorylation of tau, a critical step in the formation of neu-
roﬁbrilar tangles. Interestingly, this process was shown to be
blocked by a7-selective antagonists as well as by anti-sense knock-
down of a7 AChR protein both in cell lines and human brain syn-
aptosomes [23,24]. It was also reported that chronic nicotine
intake causes a marked increase in the aggregation and phosphor-
ylation state of tau in a transgenic model of AD [25]. The a7 AChR-
mediated high Ca2+ permeability activated either by nicotine or by
Ab causes dramatic increases in intracellular Ca2+ levels [26]. This
rise in intracellular Ca2+ activates Ca2+-dependent kinases that
could be responsible for tau phosphorylation [23,24]. The accumu-
lation of intraneuronal Ab occurs prior to plaque and neuroﬁbrilar
tangle formation and a selective decrease in Ab42 markedly delays
the progression of tau pathology [27]. Hence, tau hyper-phosphor-
ylation and its deposit as neuroﬁbrilar tangles seem to be a down-
stream event to aberrant processing of APP. The in vitro and in vivo
data therefore suggest that a7 AChR can operate as a link between
Ab and tau pathology. Whether Ab activates or inhibits the a7
AChR in vivo is still controversial; it is nonetheless clear from sev-
eral studies using a variety of preparations that prolonged expo-
sure to a moderate concentration of soluble Ab leads to AChR
antagonism, possibly through a desensitization mechanism. All
studies conclude, however, that there is a direct or indirect interac-
tion between the Ab and the a7 AChR and that the latter may
somehow catalyze the toxic effects exerted by the Ab. All things
considered, evidence of a link between Ab and a7 AChRs is over-
whelming. However the consequences of this interaction need to
be clariﬁed.
AD is a chronic disease with a very long asymptomatic period. In
animalmodels of thedisease, suchas transgenic rat andmousemod-
elswithAb accumulation, deﬁcits in synaptic transmission andplas-
ticity occur before amyloid plaque accumulation [25,27,28],
suggesting that it is the soluble, non-ﬁbrilary species of Ab that plays
amajor role in AD pathogenesis. The chronology of these events fur-
ther suggests that AD is, ab initio and foremost, a ‘‘synaptopathy”. To
understand themechanism forAb toxicity at the synaptic levels is, in
our view, one of the core issues in the ﬁeld of AD.3. Cholesterol and the AChR
Cholesterol is a very abundant component of the synaptic
membrane where the AChR is located [29]. Cholesterol affects
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protein, its trafﬁcking from the site of synthesis to the cell surface,
its spatio-temporal distribution and organization – including clus-
tering – at the plasmalemma, its rate of endocytosis, and even sin-
gle-channel behavior [29]. The most important message that
emerges from two decades of research on the effect of the sterol
on the muscle-type AChR is that cholesterol effects on the receptor
protein are multiple, are exerted at various levels of organization –
ranging from the molecular to the cellular level – and occur within
multiple time windows, covering the millisecond (single-channel
properties) to the minute and hour (endocytic/exocytic trafﬁcking)
time scales, during ontogenetic development and adulthood [30].
The neuronal a7 AChR was the ﬁrst to be suggested to occur in
lipid ‘‘rafts” at the surface of the somatic spines in chick ciliary gan-
glion sympathetic neurons [31]. The association of AChR with lipid
‘‘rafts” was postulated on the basis of biochemical criteria: cold
detergent extraction procedures combined with subcellular frac-
tionation techniques resulting in detergent-resistant (DRM) and
detergent-soluble fractions. The DRMs are thought to represent li-
quid order (lo) domains, which coexist in the same membrane with
liquid disorder (ld) domains [32]. The resistance of lo domains to
detergent solubilization is ascribed to the close packing of lipids
in the lo phase, which prevents detergent incorporation into the bi-
layer [33]. When the peripheral, muscle-type AChR was overex-
pressed in COS-7 cells the receptor protein was found to be
present in the DRM fraction obtained by cold 1% Triton X-100
extraction followed by gradient centrifugation [34]. In the muscle
cell line C2C12, the stability of AChR aggregates was found to de-
pend on cholesterol content [35]. Using CHO-K1/A5 cells, a clonal
cell line that expresses adult muscular AChR [36,37], it was dem-
onstrated that chronic cholesterol depletion by treatment with
the drug Mevinolin decreases cell-surface AChRs by inhibition of
receptor exocytosis and retention of the protein at the Golgi com-
plex. Acute cholesterol depletion of CHO-K1/A5 cells with methyl-
b-cyclodextrin reduced the amount of muscle type cell-surface
AChR by accelerating receptor endocytosis [22]. Stimulated emis-
sion depletion superresolution microscopy [38] reported changes
in the distribution of AChR particles after cholesterol depletion.
We also found that cholesterol depletion affects AChR mobility at
the plasma membrane as measured by ﬂuorescence recovery after
photobleaching and ﬂuorescence correlation spectroscopy [39].
More recently, we investigated whether the paradigm Torpedo
AChR protein favors lipid ordered domains: the AChR was found
not to display any preference for a liquid-ordered or disordered li-
pid domain. In fact, Torpedo AChR behaves in vitro as a DRM-dis-
ruptor [40]. This extensive series of studies strongly supports the
notion of a close correlation between AChR and cholesterol, but
the occurrence of the protein and the sterol within a ‘‘raft” domain
is still a contentious issue: the effects of detergents on biological
membranes are much too complex and in many cases ‘‘raft” mark-
ers are spatially segregated in the membrane into physically dis-
tinct compartments, their association upon subcellular
fractionation and detergent extraction being man-tailored rather
than reﬂecting the nanoscale organization in situ [41].4. Cholesterol in AD
Cholesterol biosynthesis and catabolism are affected in AD,
mainly because APP processing and Ab production depend on
membrane cholesterol content and on levels of isoprenoid inter-
mediates in cholesterol biosynthesis (Fig. 2). The role of cholesterol
as a risk factor for AD remains controversial [42,43]. Several stud-
ies have sought an association between hypercholesterolemia,
mainly in mid age, and increased susceptibility to sporadic late-on-
set AD [42]. It is also well known that the brain is one of the tissueswith the highest levels of cholesterol. This endogenous sterol is
very important in the CNS because of its capacity to modulate syn-
aptic plasticity, membrane ﬂuidity, and the function of various
membrane proteins, including ion channels [29]. The ﬁrst connec-
tion between a defect in cholesterol metabolism and AD came with
the observation that the heritage of the e4 allele of the ApoE, the
principal cholesterol transport protein in the brain, constituted a
risk factor for the disease, a subject that will be developed in a sep-
arate section of this review.
Genetic studies of the risk of AD have reported association with
polymorphisms in three other cholesterol related genes: choles-
terol 24-hydroxylase, ATP-binding cassette transporter A1 (ABCA1)
and lipoprotein receptor-related protein [44–46]. The possible link
between abnormal cholesterol homeostasis and AD is currently
viewed as a major physiopathological relationship. The mecha-
nisms underlying such link are far from being understood and
seem to be a complex network affecting diverse aspects of the dis-
ease. There is evidence suggesting the involvement of cholesterol
in APP metabolism, in the susceptibility of neurons to Ab toxicity,
in the progression of tau pathology and in the correct function of
synapses [20,47]. Thus, many steps in the development of AD
may be affected by altered levels of cholesterol (Fig. 3).
Some statins (atorvastatin, simvastatin, lovastatin), used for the
treatment of hypercholesterolemia, can cross the BBB and have
been proposed as possible pharmacological agents in the treatment
of AD. This is supported by clinical studies indicating that individ-
uals chronically treated with these drugs display lower risk of
developing late-onset AD [48]. Furthermore, cultured hippocampal
cells as well as neuroblastoma cells that express the amyloidogenic
Swedish mutation of APP reduced the production of Ab when trea-
ted with statins, possibly as a combination of lowered geranylger-
anyl isoprenoids synthesis [49], increased a-secretase activity [50]
and decreased inﬂammatory response when exposed to Ab aggre-
gates [51]. In conclusion, statins may contribute to the homeostasis
of cholesterol distribution in cell membranes and provide an anti-
inﬂammatory effect, beneﬁcial for AD patients. Similarly, increased
consumption of polyunsaturated fatty acids (notably the omega-3
family) associated with a low intake of hydrogenated fats has been
reported to reduce the risk of developing AD and other dementias,
particularly those associated with vascular alterations [42]. In
addition, vascular injury has been shown to affect the translocation
of cholesterol-carrying lipoproteins in the CNS, leading to increases
in membrane cholesterol. This in turn can affect the regulation of
secretase activity and the generation of Ab peptides [52]. The latter
can enhance vasoconstriction, reduce cerebral blood ﬂow [53] and
increase ROS production [54]. These chains of events worsen vas-
cular endothelial damage and reduce brain parenchyma perfusion
with more atheromatous plaques [55]. The data could explain, at
least in part, why age and high blood cholesterol constitute main
risk factors for sporadic AD.5. Apolipoproteins and AChR
ApoE is the main apolipoprotein in cerebrospinal ﬂuid and is
essential for the normal catabolism of triglyceride-rich lipoprotein
constituents and the transport of fat-soluble vitamins and choles-
terol. ApoE is also involved in neuronal development and regener-
ation. The ApoE is a polymorphic gene mapped to chromosome 19
and encodes a 299 amino acid long class of apolipoprotein. There
are three isoforms of ApoE: ApoE2 (Cys112, Cys158; e2), ApoE3
(Cys112, Arg158; e3), and ApoE4 (Arg112, Arg158; e4), which differ
from one another only by a single amino acid substitution [56,57]
and exhibit different conformation and lipid-binding properties.
ApoE binds to the seven identiﬁed mammalian members of the
highly conserved low-density lipoprotein receptor (LDLR) family
Fig. 2. APP metabolism by the secretase enzymes. APP can be sequentially cleaved by b-secretase and c-secretase, to generate Ab in an amyloidogenic pathway, or be
hydrolyzed by a-secretase and c-secretase to follow the non-amyloidogenic pathway. In the amyloidogenic pathway, b-secretase cleavage of APP releases APPsb, an
ectodomain secreted to the extrasynaptic space, and C99, a membrane-bound fragment. C99 is a substrate for c-secretase, and its cleavage generates the APP intracellular
domain together with the C-terminus of Ab. In the non-amyloidogenic pathway, a-secretase cleaves APP to generate the secreted ectodomain, APPs a and membrane-bound
fragment C83. The latter is subsequently cleaved by the c-secretase complex to yield the 3 kDa fragment, P3, and the APP intracellular domain.
Fig. 3. Cholesterol, Ab and AChR. Cholesterol exerts a homeostatic ﬁne tuning of muscle-type AChR function, number and distribution at the cell surface: cholesterol
depletion lengthens the AChR channel mean open time and reduces receptor cell-surface levels by increasing the rate of endocytosis, and increases the size of AChR
nanoclusters and their ‘‘social” supramolecular organization [29]. In the CNS cholesterol also modulates secretase activities: increased levels of cholesterol augment b and c
secretase activities with a consequent rise in Ab production. Ab interacts with a7 AChR and promotes receptor internalization. Ab aggregation can in turn reduce cellular
cholesterol content by inhibiting 3-hydroxy-3-methyl-glutaryl-CoA (HMGCoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis [77]. Decreased levels of
cholesterol have been reported to promote AChR endocytosis [22] therefore worsening this scenario. This sequence of events leads to a cycle that regulates cholesterol levels.
Although statins inhibit HMGCoA reductase activity, resulting in lower cholesterol levels, these drugs can also increase a-secretase activity [50], thus rescuing the cell from
certain death.
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mately involved in neuronal signal transduction, modulation of li-
gand-gated ion channels, and control of neurite outgrowth,
synapse formation and neuronal migration [59]. The ApoE4 protein
isoform has gained importance for its unequivocal role as a genetic
risk factor for late-onset AD [60] with a strong gene-dosage effect
such that the number of ApoE4 alleles correlates positively with
the risk of developing AD and the age of onset [60] and negativelywith the number of AChR binding sites in patients with AD, as well
as with responsiveness to the therapeutic AChE inhibitor tacrine
[61]. The ApoE3 isoform is described as having no effect on AD risk
and the ApoE2 isoform expression appears in fact to decrease the
risk of disease as compared to ApoE3 [60]. Although the mecha-
nisms underlying the pathogenic effects of the ApoE4 phenotype
are not completely understood, there is evidence that ApoE4
promotes toxic Ab42 production, aggregation, and amyloid plaque
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Ab peptide than the other ApoE isoforms [63], thus reducing its
ability to clear Ab peptides from neurons favoring Ab intracellular
accumulation and oligomerization [63]. Furthermore, recent obser-
vations demonstrate that oligomers, which are the most toxic form
of Ab, are internalized more effectively than the less toxic ﬁbrillar
forms [64]. In addition, there is the possibility that multiple path-
ways may be involved in the pathogenic effects of ApoE4 since
there are reports that enhanced proteolytic degradation of ApoE4
is associated with production of toxic fragments [65,66] and with
having reduced uptake by the low-density lipoprotein receptor
(LDLR) [67].
ApoE has been shown to directly interact with AChRs [68–70].
Experiments using peptides derived from the LDLR binding domain
of ApoE resulted in inhibition of the endogenous expression of
AChRs in interneurons from rat hippocampal slices, with a submi-
cromolar afﬁnity, and of heterologously expressed a7, a4b2 and
a2b2 AChRs. Furthermore, this effect selectively affected members
of the Cys-loop family of receptors having permeability to cations,
since neither glycine nor GABA receptors were sensitive to block
[69]. The latter action is dependent on an arginine-rich segment
of the ApoE peptide [68] whereas the degree of the block was
greater for the a7 AChRs than that for a4b2 or a2b2 AChRs [69].
Interestingly, ApoE peptides were unable to block functional a-
bungarotoxin (a-BTX) binding. This could indicate that the pep-
tides do not interact with a7 AChRs in a competitive fashion, but
rather at a site other than the traditional ligand-recognition site
or at the interface between subunits at a distinct ‘‘microsite” that
does not preclude a-BTX binding [69]. ApoE peptides behave,
therefore, as non-competitive antagonists of a7 AChRs. Further-
more, the block of a7 AChRs is abolished when Trp55 is mutated
to alanine, suggesting that it results from a direct interaction be-
tween the peptide and the a7 AChR [70]. From these ﬁndings,
the inference has been made that ApoE may contribute to cognitive
decline by interfering with cholinergic neurotransmission [70].
In summary, several studies suggest that impairment of mem-
ory function [71] and synaptic loss [72] is associated with ApoE4
in transgenic mice models. Since a7 AChRs are linked to cognitive
function, and dysfunctions in these receptors are thought to be in-
volved in the cognitive decline associated with AD [73], their inhi-
bition by ApoE-derived peptides or ApoE fragments containing the
LDLR binding domain could have deleterious consequences for
cognition and/or cell viability. It is possible that this adverse inter-
action is responsible for at least some of the cognitive impairments
observed in AD.6. Lipid metabolism, APP processing and AChR
APP is a conserved type I membrane protein. It is highly ex-
pressed in central and peripheral nervous systems, and can be
detected in both pre- and postsynaptic compartments [74,75].
The physiological role of APP is still a matter of debate. There
is growing evidence that APP and its cleavage products are
important modulators of synapse formation and function
(Fig. 2). Hippocampal neurons from APP knockout mice show
enhanced excitatory synaptic transmission and this effect was
attributed to the production of Ab peptides since it was
reproduced in normal neurons treated with presenilin inhibitors
and in neurons from presenilin-1 (PS1) knockout mice [76].
Moreover, developmental overexpression of dendritic APP or Ab
increases susceptibility to seizures, and mediates presynaptic
localization and activity of the high-afﬁnity choline transporter,
consistent with a role of APP in the proper function of
synaptic transmission in both the NMJ and central cholinergic
neurons.The ubiquitous presence of APP and its processing enzymes, the
presenilins, suggests that their range of action is not restricted to
the CNS [77]. In fact, APP may function as a regulator of lipid
metabolism. There is a mutual interaction between the generation
of Ab peptide and cholesterol metabolism, hypercholesterolaemia
being an early risk factor in the development of AD [78]. In addi-
tion, increased levels of cholesterol augment b and c secretase
activities with a consequent rise in Ab production [47]. Ab40
may in turn reduce cellular cholesterol content by inhibiting 3-hy-
droxy-3-methyl-glutaryl-CoA (HMGCoA) reductase, the rate-limit-
ing enzyme in cholesterol biosynthesis [77]. Since reduced levels of
cholesterol diminish the production and secretion of Ab40 and
Ab42 [47] this sequence of events may function as a cycle to regu-
late cholesterol levels [79] (Fig. 3). The relationship between Ab
levels and cholesterol appears to be biphasic and to operate within
a certain range of cholesterol concentrations [79]. In contrast, Ab42
activates sphingomyelinase and reduces the levels of sphingomye-
lin in the cell [77]. The Ab40/42 ratio can thus modulate the lipid
composition of the cell. Interestingly, in AD brains this ratio is al-
tered with an increase in the levels of Ab42. A change in Ab40/42
ratio should cause or be the consequence of an altered lipid
homeostasis, as occurs in AD [77].
Alterations in the lipid composition of the cell membrane may
result in changes in the activity of many membrane-bound pro-
teins. As such, neuronal and muscle AChRs have been shown to
be especially sensitive to the lipid environment [80] and this prop-
erty may contribute to the pathology of AD. Neuronal a7 AChR
have been reported to be associated with cholesterol-rich mem-
brane fractions and this association increases during synaptogene-
sis [31,81]. In contrast, b2 and a5 AChR subunits do not show such
an association, pointing to a speciﬁc membrane localization of a7
AChRs. Moreover, a reduction in cholesterol levels results in the
dispersal of a7 AChR clusters in somatic spines of ciliary ganglion
neurons, suggesting that cholesterol is necessary for the localiza-
tion of a7 AChR at speciﬁc sites in the membrane [31]. The same
phenomenon occurs with muscle AChR: cholesterol was shown
to be required for the formation and maintenance of the large clus-
ters found at the neuromuscular junction [35] and the submicron-
sized clusters found in CHO cells [22,38]. Furthermore, chronic,
long-term cholesterol depletion attained by metabolic inhibition
of its biosynthetic pathways disrupts the cell surface delivery of
AChR in CHO cells [37]. It is not only AChR localization and stability
in the membrane that are dependent on cholesterol; signal trans-
duction through the a7 AChR is disrupted when cholesterol levels
are reduced in PC12 cells [81] and channel properties of muscle
AChR are altered too [22,29]. Thus, the disruption of cholesterol
homeostasis observed in the AD brain could speciﬁcally affect cho-
linergic synapses and may contribute to the observed decrease in
the number of AChRs.7. Astrocytes, inﬂammation and Ab
Whereas the effect of Ab on neurons has been studied quite
thoroughly, less is known about the action of the amyloid peptide
on astrocytes. Astrocytes play major roles in both normal and dis-
eased brain [82]. It has been observed that these cells are activated
in AD, and Ab can directly activate cultured astrocytes [83]. More-
over, the astrocytes that accumulate deposits of Ab can degrade
these peptides [84]. Interestingly, the a7 AChR levels in astrocytes
of brains with sporadic AD is high [85]. This was also observed in
the brains of patients carrying the Swedish APP 670/671 mutation
[85]. These high levels of a7 AChR expression may be a conse-
quence of the stimulation of astrocytes by internalized Ab or be re-
lated to the severity of AD pathology [86]. Furthermore, Ab42
positive astrocytes in the molecular layer of the cortex of AD
1862 F.J. Barrantes et al. / FEBS Letters 584 (2010) 1856–1863patients exhibit intense and speciﬁc immunostaining for a7 AChR
[87]. The mechanism implicated in the Ab-induced upregulation of
a7 AChRs in astrocytes is still unclear. Interestingly, upregulation
of a7 AChRs was also reported in mouse hippocampal slices after
chronic exposure to Ab at concentrations typically found in the
brains of AD patients and in animal models of AD [88]. In the latter
study, a7 AChR upregulation was a consequence of Ab activation of
the ERK2 MAPK cascade via a7 AChR [88]. Whether this is also the
mechanism responsible for a7 AChR upregulation in astrocytes re-
mains to be studied. Alternatively, microglia can exert neuropro-
tective functions by secreting growth factors or diffusible anti-
inﬂammatory mediators, which help resolve inﬂammation and re-
store tissue homeostasis [89]. Since AChRs play an important role
in neuroprotection [90], this elevated expression of a7 AChR by
astrocytes might thus represent a defense or compensatory mech-
anism to stimulate the production of suitable amounts of Ab.
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